Related Experiment Video
Updated: Jun 30, 2026
Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
Published on: January 13, 2018
Esketamine for negative emotions and cognitive function in general anesthesia: a systematic review and meta-analysis
Xiaofan Yang1, Jing Qin1, Wenqing Xu1
1Department of Anesthesiology, Tinglin Hospital, Shanghai, China.
Introduction:
This study aims to systematically evaluate, through a systematic review and meta-analysis, the effect of esketamine on postoperative negative emotions (anxiety and depression) and cognitive function in patients undergoing general anesthesia.
Methods:
Following PRISMA guidelines, we systematically searched PubMed, Web of Science, Embase, Cochrane Library, and CNKI to identify studies up to April 2025. Included randomized controlled trials (RCTs) involved adults undergoing general anesthesia, comparing perioperative esketamine to placebo/standard care, and reporting outcomes on negative emotions or cognitive function. Risk of bias was evaluated using Cochrane RoB 2.0, and Data were synthesized using R 4.3.3 with random-effects models; heterogeneity and robustness were assessed via I2 statistics and sensitivity analyses.
Results:
Thirteen RCTs involving 1,312 patients were included. Esketamine significantly reduced depressive (SMD = -0.92, 95% CI: [-1.39, -0.46]) and anxiety symptoms (SMD = -1.23, 95% CI: [-1.71, -0.75]), with low certainty of evidence for both outcomes. Cognitive outcomes were heterogeneous: MMSE showed no significant effect overall (SMD = 0.22, 95% CI: [-0.87, 1.30]) but became significant after excluding an outlier (SMD = 0.65, 95% CI: [0.39, 0.90]), while MoCA results remained non-significant (SMD = 0.93, 95% CI: [-0.99, 2.84]), and the certainty of evidence for MMSE and MoCA was rated very low.
Conclusion:
Esketamine demonstrates robust antidepressant and anxiolytic effects postoperatively, while its cognitive benefits remain unclear owing to high heterogeneity and very low evidence certainty. Although these findings support the potential application of esketamine in perioperative emotional management, the low to very low overall certainty of evidence justifies the need for further high-quality, large-scale RCTs to clarify its cognitive effects and establish optimal dosing regimens.
Systematic Review Registration:
Identifier, CRD420251078985.
Related Concept Videos
01:24General Anesthesia: Overview
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
01:24Parenteral Anesthetics: Overview
01:22Stages of General Anesthesia
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:20Inhalational Anesthetics: Overview